Sanofi posted 17.8% Q2 2026 sales growth at constant exchange rates, driven by Dupixent’s record €5.2 billion quarter and a 48.3% jump in pharma launches, prompting an upgraded full-year outlook.
Sanofi has discontinued amlitelimab in moderate-to-severe atopic dermatitis and will not pursue global regulatory submissions, citing ESTUARY phase 3 data that did not show a meaningful edge over standard of care. Full-year 2026 guidance is unaffected.
Sanofi’s Sarclisa Escena has been approved by the FDA as the first anticancer treatment deliverable via an on-body injector, offering multiple myeloma patients a faster, needle-free-feeling alternative to IV infusions.
Sanofi has achieved a historic breakthrough with the expanded Tzield FDA approval for young children. Previously restricted to those aged eight and older, the therapy is now available for children as young as one year old, offering a vital window to delay the onset of clinical Type 1 Diabetes.
Sanofi anticipates that the US regulatory decision for its investigational drug, tolebrutinib, for non-relapsing secondary progressive multiple sclerosis (nrSPMS) will be delayed beyond the previous December 2025 target action date, with further guidance expected by the end of Q1 2026.
A groundbreaking real-world study has revealed that Beyfortus (nirsevimab-alip) significantly reduces the incidence of respiratory syncytial virus (RSV) disease in infants. The largest of its kind in the United States, the study demonstrated an 87% reduction in RSV cases requiring a visit to a doctor or hospital and a 98% decrease in hospitalizations among infants who received the treatment.
The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as the first and only targeted biologic treatment for adults with bullous pemphigoid, a rare and debilitating autoimmune skin disease.
Sanofi made early Q3 global availability of BEYFORTUS® (nirsevimab) to stock up on the healthcare providers ahead of the 2025–2026 respiratory syncytial virus (RSV) season, which generally runs from November through March. Advancements in Immune Thrombocytopenia (ITP) Sanofi shared Phase 3 LUNA [Read More…]
Sanofi unveiled promising new data at ISTH 2025, spotlighting rilzabrutinib’s potential in immune thrombocytopenia and reinforcing its leadership in hemophilia care through advancements with ALTUVIIIO and QDENGA.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
